Alpha lipoic acid and HbA1c have become a growing topic of interest among people managing type 2 diabetes and prediabetes. Alpha lipoic acid (ALA) is a naturally occurring antioxidant compound found in foods such as spinach and broccoli, and is widely available as an over-the-counter supplement in the UK. Some research suggests ALA may modestly influence blood glucose markers, including HbA1c — the standard NHS measure of long-term glycaemic control. However, clinical evidence remains inconsistent, and ALA is not currently recommended by NICE or the NHS for diabetes management. This article examines the evidence, safety considerations, and relevant UK guidance.

What Is Alpha Lipoic Acid and How Does It Work?

ALA is a mitochondrial antioxidant cofactor that may improve insulin sensitivity via AMPK activation, but clinical evidence for a meaningful effect on HbA1c is inconsistent and it is not approved by the MHRA or recommended by NICE for diabetes.

Alpha lipoic acid (ALA) is a naturally occurring organosulphur compound synthesised in small quantities by the human body and found in foods such as spinach, broccoli, and red meat. It functions as a cofactor for mitochondrial enzyme complexes involved in energy metabolism, and is notable for its antioxidant properties. Unlike many antioxidants, ALA is both water- and fat-soluble, allowing it to act across a range of biological environments, including cell membranes and cytoplasm.

From a pharmacological standpoint, ALA works by scavenging reactive oxygen species (ROS) and regenerating other antioxidants such as vitamins C and E and glutathione. Oxidative stress is widely recognised as a contributing factor in the development and progression of type 2 diabetes and its complications, particularly diabetic peripheral neuropathy.

Some research — largely preclinical and limited human studies — has suggested that ALA may enhance insulin sensitivity by activating AMP-activated protein kinase (AMPK), a key regulator of glucose and lipid metabolism. These mechanistic findings have generated interest in whether ALA supplementation could influence glycaemic control markers, including HbA1c. HbA1c is a blood test used to measure average blood glucose levels over approximately three months; the NHS uses it as the standard measure for diagnosing and monitoring diabetes.

However, clinical evidence for a meaningful effect on HbA1c in humans is inconsistent, and effect sizes reported in trials are generally small and variable. ALA is not currently approved as a treatment for diabetes or glycaemic management by the MHRA, and it is not recommended by NICE or the NHS for this purpose.

Who Might Benefit From Alpha Lipoic Acid Supplementation?

People with type 2 diabetes or diabetic peripheral neuropathy are the most studied groups, but evidence for HbA1c reduction is inconsistent and ALA is not recommended by NICE or the NHS for glycaemic control.

The population most studied in relation to ALA supplementation includes individuals with type 2 diabetes, prediabetes, and those experiencing diabetic peripheral neuropathy. Several randomised controlled trials and meta-analyses have examined ALA's effect on HbA1c, fasting blood glucose, and insulin resistance markers such as HOMA-IR. Whilst some studies report modest reductions in these markers, findings are inconsistent across trials, effect sizes are often small, and it is not established that any reductions are clinically meaningful. ALA supplementation is not recommended by NICE or the NHS for improving glycaemic control.

Individuals with diabetic peripheral neuropathy represent a group with more studied potential benefit. Intravenous ALA (thioctic acid) is nationally authorised in some EU member states — such as Germany — for symptomatic diabetic neuropathy; however, it does not hold a central EMA authorisation, and no ALA product is licensed by the MHRA in the UK for any indication. Symptoms such as burning, tingling, and numbness in the extremities may be reduced with ALA in this context, though this evidence is more robust than that for HbA1c reduction specifically.

People with metabolic syndrome or insulin resistance who have not yet progressed to a formal diabetes diagnosis are sometimes considered as potential candidates for ALA supplementation. However, evidence in this group remains limited, and there is currently insufficient evidence to recommend ALA for prediabetes or metabolic syndrome in routine UK clinical care. Supplementation should not be used as a substitute for evidence-based interventions such as dietary modification, physical activity, and prescribed medication.

There is currently insufficient evidence to recommend ALA supplementation for people with type 1 diabetes. ALA should be avoided in pregnancy and breastfeeding unless a clinician has specifically advised otherwise, as safety in these groups is not established.

Individuals considering ALA should:

• Consult their GP or diabetes care team before starting supplementation

• Not adjust prescribed diabetes medications without medical advice

• Disclose all supplements during clinical consultations to avoid unrecognised interactions

Recommended Doses, Forms, and Safety Considerations

Most trials use 300–1,200 mg daily orally, with 600 mg daily most commonly studied; key risks include gastrointestinal side effects, hypoglycaemia, and the rare but serious insulin autoimmune syndrome (IAS).

ALA is available in several forms, including racemic ALA (a mixture of R- and S-isomers) and R-ALA (the naturally occurring form). R-ALA is often described as more bioavailable than the racemic mixture, though bioavailability varies considerably depending on the formulation and salt form used, and product quality across the supplement market is inconsistent. Most clinical trials investigating effects on HbA1c and glycaemic markers have used doses ranging from 300 mg to 1,200 mg per day, typically administered orally in divided doses. Intravenous formulations have been used in clinical settings for neuropathy in some countries, but are not routinely available in the UK outside specialist care.

For general supplementation purposes, doses of 600 mg daily are most commonly studied and appear to offer a reasonable balance between efficacy and tolerability. Higher doses may increase the risk of adverse effects without proportionate benefit. ALA supplements are classified as food supplements in the UK and are not regulated to the same standard as licensed medicines by the MHRA. Quality, dose accuracy, and bioavailability can therefore vary significantly between products.

Common adverse effects associated with oral ALA supplementation include:

• Gastrointestinal symptoms — nausea, vomiting, and abdominal discomfort, particularly when taken on an empty stomach

• Headache and dizziness, especially at higher doses

• Skin rash or allergic reactions in rare cases

• Hypoglycaemia (low blood sugar), particularly when taken alongside glucose-lowering medications

A rare but serious adverse effect is insulin autoimmune syndrome (IAS), which can cause recurrent, unpredictable, and severe hypoglycaemia. If unexplained or recurrent episodes of low blood sugar occur whilst taking ALA, supplementation should be stopped immediately and urgent medical advice sought.

Individuals with thiamine (vitamin B1) deficiency — including those with a history of chronic alcohol misuse — should exercise particular caution, as ALA may theoretically worsen thiamine deficiency. Long-term safety data beyond 12 months remain limited.

Patients should be advised to stop supplementation and seek medical advice if they experience unexplained symptoms, particularly signs of low blood sugar such as shakiness, sweating, or confusion. Suspected adverse reactions to ALA supplements should be reported to the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk.

Interactions With Diabetes Medications and Other Treatments

ALA carries the greatest hypoglycaemia risk when combined with sulphonylureas or insulin, and may also interact with levothyroxine, mineral supplements, and cisplatin chemotherapy.

One of the most clinically significant considerations when discussing alpha lipoic acid and HbA1c management is the potential for pharmacodynamic interactions with prescribed diabetes medications. Because ALA may independently lower blood glucose through improved insulin sensitivity, combining it with glucose-lowering agents could increase the risk of hypoglycaemia.

This risk is most clinically relevant for patients taking sulphonylureas (e.g., gliclazide) or insulin, where hypoglycaemia is already a recognised adverse effect of the medication itself. The additional hypoglycaemia risk when combining ALA with metformin or SGLT-2 inhibitors used as monotherapy is considered low, as these agents do not typically cause hypoglycaemia on their own; however, caution remains appropriate in combination regimens. Patients on sulphonylureas or insulin should be counselled to monitor blood glucose more frequently when initiating ALA supplementation and to report any episodes of low blood sugar to their diabetes care team promptly. Dose adjustments to prescribed medications should only be made under medical supervision.

ALA may also interact with levothyroxine (used in hypothyroidism). Evidence for this interaction is limited and largely theoretical, but as a precaution it is advisable to separate administration by at least two to four hours and to inform the prescribing clinician. There is also some evidence suggesting ALA may chelate minerals such as iron, magnesium, and zinc; individuals taking mineral supplements or with known deficiencies should seek guidance on timing of doses, and it is generally advisable to separate ALA from mineral supplements by at least two to four hours.

There is also a potential interaction with cisplatin (a chemotherapy agent): ALA may theoretically reduce its effectiveness, as noted in some product information for thioctic acid. Patients receiving chemotherapy should inform their oncology team before taking ALA.

From a pharmacokinetic perspective, ALA is best absorbed on an empty stomach, approximately 30 minutes before meals, as food can reduce its bioavailability. Patients should be encouraged to:

• Inform their GP and pharmacist of all supplements being taken

• Avoid self-adjusting prescribed medication doses based on perceived supplement effects

• Report any new or worsening symptoms promptly, including fatigue, dizziness, or changes in blood glucose readings

Current NHS and NICE Guidance on Antioxidant Supplements in Diabetes

Neither NICE nor the NHS recommends ALA supplementation for diabetes management or HbA1c reduction; no ALA product holds MHRA marketing authorisation in the UK.

At present, neither NICE nor the NHS formally recommends alpha lipoic acid supplementation as part of standard diabetes management or for the purpose of reducing HbA1c. NICE guidelines for type 2 diabetes (NG28) and type 1 diabetes (NG17) focus on evidence-based pharmacological and lifestyle interventions; antioxidant supplements, including ALA, are not included within these frameworks and are not recommended for glycaemic control. This does not mean ALA is considered harmful, but rather that the current evidence base is not sufficient to support a formal clinical recommendation.

NICE's approach to diabetes management emphasises individualised care, structured education programmes such as DESMOND and DAFNE, dietary modification, physical activity, and stepwise pharmacological therapy. In line with NICE NG28, HbA1c targets are individualised, but as a general guide:

• 48 mmol/mol (6.5%) is the target for adults with type 2 diabetes managed by lifestyle and diet alone, or with a single drug not associated with hypoglycaemia

• 53 mmol/mol (7.0%) is the target for adults on a drug regimen associated with hypoglycaemia risk (e.g., sulphonylureas or insulin)

• Targets should be adjusted based on individual circumstances, comorbidities, and patient preference

Any intervention — including supplementation — that claims to influence HbA1c should be evaluated within this broader clinical context.

No ALA product is licensed by the MHRA as a medicinal treatment in the UK. Intravenous ALA (thioctic acid) is nationally authorised in some EU member states for symptomatic diabetic peripheral neuropathy, but this does not represent a central EMA authorisation, and it does not extend to oral supplementation for glycaemic control. Patients should be made aware that food supplement labelling is not subject to the same rigorous standards as licensed medicines, and claims made on product packaging may not reflect the strength of clinical evidence.

Healthcare professionals should adopt a non-judgemental approach when patients raise questions about ALA and HbA1c, providing balanced information about the current evidence, potential benefits, and safety considerations. Patients should be encouraged to raise supplement use at every diabetes review, to prioritise NICE-recommended interventions as the foundation of their diabetes management plan, and to report any suspected adverse reactions via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk.

Frequently Asked Questions